Skip to main content

Table 1 Comparisons of different groups in terms of renal function before and after treatments

From: Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model

 

BUN before treatment (mg/dL)

BUN after treatment

(mg/dL)

Cr before treatment

(mg/dL)

Cr after treatment

(mg/dL)

Body weight (g)

SBP (mmHg)

DBP (mmHg)

Control

15.83 ± 1.6

15.33 ± 3.88

0.73 ± 0.05

0.7 ± 0.18

588.83 ± 44.74

125.50 ± 5.58

73.33 ± 4.18

CKD

35.15 ± 4.18#

45.83 ± 4.96*,$

0.82 ± 0.20

1.7 ± 0.43*,$

551.67 ± 25.10

164.83 ± 7.31$

86.33 ± 4.5$

CKD + ALT-711

32.5 ± 7.48#

46 ± 17.32*,$

0.90 ± 0.22

1.82 ± 0.76$

585.67 ± 48.30

161.83 ± 5.95$

83.50 ± 4.72$

CKD + SPL

37.5 ± 8.17#

43.83 ± 18.09$

1.08 ± 0.33

1.32 ± 0.33$

562.50 ± 54.24

165.17 ± 6.18$

85.00 ± 3.58$

  1. BUN blood urea nitrogen, Cr creatinine, CKD chronic kidney disease, SPL spironolactone, SBP systolic blood pressure, DBP diastolic blood pressure, * Before treatment versus. After treatment, p < 0.05; # any groups compared with the control group before treatment, p < 0.05, $ any groups compared with the control group after treatment, p < 0.05